149PD - Association between early tumour shrinkage (ETS) and outcomes in RAS-wild type (WT) patients (pts) with metastatic colorectal cancer (mCRC) receivi...

Date 20 December 2015
Event ESMO Asia 2015 Congress
Session Gastrointestinal tumours
Topics Anticancer Agents
Colon and Rectal Cancer
Biological Therapy
Presenter Ann-Lii Cheng
Citation Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523
Authors A. Cheng1, G.H. Cornelio2, L. Shen3, T.J. Prince4, T. Yang5, I. Chung6, G. Dai7, J. Lin8, A. Sharma9, K. Yeh10, B.B. Ma11, A. Zaatar12, Z. Guan13, N. Masood14, V. Srimuninnimit15, T. Cheung Yau16, F. Beier17, S. Chatterjee18, R. S.c. Lim19
  • 1Oncology, National Taiwan University Hospital, 100 - Taipei/TW
  • 2Oncology, San Juan de Dios Hospital, 300 - Pasay City/PH
  • 3Oncology, Peking University Cancer Hospital-Beijing Cancer Hospital, haidian - Beijing/CN
  • 4Oncology, Queen Elizabeth Hospital, Woodville/AU
  • 5Oncology, Chang Gung Memorial Hospital-Linkou, Taoyuan/TW
  • 6Oncology, Chonnam National University Hwasun Hospital, Hwasun-Gun/KR
  • 7Oncology, General Hospital of Chinese People's Armed Police, Beijing/CN
  • 8Oncology, Taipei Veterans General Hospital, Taipei/TW
  • 9Oncology, All India Institute of Medical Sciences, New Delhi/IN
  • 10Oncology, National Taiwan University Hospital, Taipei/TW
  • 11Oncology, Chinese University of Hong Kong Prince of Wales Hospital, Hong Kong/CN
  • 12Oncology, Mount Miriam Hospital, Penang/MY
  • 13Oncology, Sun Yat-Sen University, Guangzhou/CN
  • 14Oncology, The Aga Khan University Hospital, Karachi/PK
  • 15Oncology, Siriraj Hospital, Mahidol University, Bangkok/TH
  • 16Oncology, Queen Mary Hospital University of Hong Kong, Hong Kong/CN
  • 17Global Biostatistics, Merck KGaA, Darmstadt/DE
  • 18Regional Medical, Merck Serono, Mumbai/IN
  • 19Oncology, National University Cancer Institute, Singapore, Singapore/SG



ETS has been associated with improved long-term outcome in pts with KRAS/RAS-WT mCRC treated with first-line weekly cetuximab in the CRYSTAL, OPUS, and FIRE-3 studies. The present analysis evaluated the association between ETS and progression-free survival (PFS) and overall survival (OS) in the RAS-WT population from the Asia-Pacific, multicentre, nonrandomized, phase 2 APEC study.


APEC enrolled 289 pts with KRAS-WT tumours. Eligible pts received cetuximab every other week + FOLFOX or FOLFIRI (investigator's choice). Study treatment continued until disease progression, dose-limiting toxicity or consent withdrawal. RAS status was assessed retrospectively by ion torrent next-generation sequencing on evaluable samples. ETS was categorized as ≥20% decrease in the sum of longest diameters of target lesions between baseline and 8 weeks after start of treatment.


Median PFS and OS in the RAS-WT population (n = 167) were 13.0 and 28.4 months, respectively; the best confirmed objective response rate was 64.7% and 10.8% of pts were converted for R0 resection. ETS, as defined above, occurred in 81.8% (130/159) of evaluable pts and was associated with longer PFS and OS (Table). Although this study was not designed to formally assess efficacy differences between treatment subgroups, there were no major differences between pts receiving FOLFOX vs FOLFIRI. There were no unexpected safety findings.

RAS-WT, ETS-Evaluable Pts ETS (n = 130) No ETS (n = 29) Total (n = 159)
OS # of events (%) 81 (62.3%) 20 (69.0%) 101 (63.5%)
HR (95% CI) 0.584 (0.357-0.954) -
Median, mo (95% CI) 30.3 (26.3-33.2) 16.4 (10.3-31.2) 28.5 (24.5-32.3)
PFS # of events (%) 90 (69.2%) 19 (65.5%) 109 (68.6%)
HR (95% CI) 0.721 (0.438-1.186) -
Median, mo (95% CI) 14.0 (11.2-14.9) 7.5 (3.6-16.6) 13.3 (11.1-14.8)


ETS at 8 weeks appears to be associated with longer PFS and OS in RAS-WT pts receiving FOLFOX or FOLFIRI + cetuximab every other week in the phase 2 APEC study. These findings are comparable to earlier subgroup analyses of analogous pivotal studies involving weekly cetuximab.

Clinical trial identification



G.H. Cornelio: Merck KGaA: receiving research funding. L. Shen, B. Ma: Merck KGaA: received honoraria. T.J. Prince, R. S.c. Lim: Merck KGaA: consulting. F. Beier: employee of Merck KGaA, Darmstadt, Germany. S. Chatterjee: employee of Merck Serono, Mumbai, India. All other authors have declared no conflicts of interest.